The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

One analyst described Cogent’s data as a “home run scenario” for bezuclastinib, which the company is positioning as a a ...

More than one quarter of the medcines cleared by the FDA’s main review office since 2015 have been cancer drugs, a tally that ...

Many proposals to reform the PBM industry miss the forest for the trees, experts said this week. Instead, Congress should go ...

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its ...

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

The high court preserved a key part of the Affordable Care Act requiring private insurers cover a range of preventive ...

Thimerosal, targeted by activists who claim it’s linked to autism, shouldn't be used in vaccines given in the U.S. this ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

New study results position Nuvalent to bring forward what it claims is a differentiated treatment for ROS1-positive lung ...